Information Provided By:
Fly News Breaks for January 23, 2018
AMRN
Jan 23, 2018 | 09:12 EDT
Cantor Fitzgerald analyst Louise Chen views this morning's announcement from Amarin as good news since the company is on track to report top-line results from the study before the end of Q3. Amarin this morning announced that its Reduce-It cardiovascular outcomes study has reported and documented more than 90% of the targeted 1,612 primary major adverse cardiovascular events. The analyst believes the shares have to room to run ahead of the data release. She keeps an Overweight rating on the name with a $10 price target.
News For AMRN From the Last 2 Days
There are no results for your query AMRN